Skip to main content

Blog

Cumberland Pharmaceuticals Announces Positive Results from Phase 2 FIGHT DMD Trial of Ifetroban for Treatment of Duchenne Cardiomyopathy

...

Sarepta Therapeutics Announces Results from Part 2 of EMBARK Study of ELEVIDYS

...

Update from PPMD’s 2025 Duchenne Healthcare Professionals Summit

...

Race to End Duchenne Kicks Off 20th Anniversary at Walt Disney World Marathon Weekend

...

PPMD Advocacy in the 119th Congress and the 47th Administration

...

Advance the Research Evolution with The Duchenne Registry

...

PPMD Hosts 2025 Duchenne Healthcare Professionals Summit in San Diego, California

...

Introducing PPMD’s Dystrophinopathy Clinical Research Network (DCRN): Advancing the Research Evolution

...

Avidity Biosciences Announces Plans to File Biologics License Application for Delpacibart Zotadirsen (AOC 1044)

...

PPMD’s Race to End Duchenne Program Celebrates 20 Years of Going the Distance to End Duchenne

...